Back to mobile site

BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)

September 23, 2024 4:00 PM EDT Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,300.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login